Corvus Pharmaceuticals CRVS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's operating income?
- Corvus Pharmaceuticals (CRVS) reported operating income of -$14.88M in Q1 2026.
- How has Corvus Pharmaceuticals's operating income changed year-over-year?
- Corvus Pharmaceuticals's operating income decreased by 49.9% year-over-year, from -$9.92M to -$14.88M.
- What is the long-term trend for Corvus Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's operating income has grown at a 2.7% compound annual growth rate (CAGR), from -$38.63M to -$42.97M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.